Spirulina platensis aqueous extracts ameliorate colonic mucosal damage and modulate gut microbiota disorder in mice with ulcerative colitis by inhibiting inflammation and oxidative stress.
- Author:
Jian WANG
1
;
Liqian SU
1
;
Lun ZHANG
1
;
Jiali ZENG
1
;
Qingru CHEN
1
;
Rui DENG
1
;
Ziyan WANG
1
;
Weidong KUANG
1
;
Xiaobao JIN
1
;
Shuiqing GUI
2
;
Yinghua XU
3
;
Xuemei LU
4
Author Information
- Publication Type:Journal Article
- Keywords: Antioxidant; Gut microbiota; Inflammation; Oxidative stress; Spirulina platensis aqueous extracts; Ulcerative colitis
- MeSH: Animals; Antioxidants/pharmacology*; Colitis/prevention & control*; Colitis, Ulcerative/metabolism*; Colon/metabolism*; Dextran Sulfate/toxicity*; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation/metabolism*; Mice; Mice, Inbred C57BL; Oxidative Stress; Reactive Oxygen Species/metabolism*; Spirulina
- From: Journal of Zhejiang University. Science. B 2022;23(6):481-501
- CountryChina
- Language:English
- Abstract: Ulcerative colitis (UC) is a chronic and recurrent inflammatory bowel disease (IBD) that has become a major gastroenterologic problem during recent decades. Numerous complicating factors are involved in UC development such as oxidative stress, inflammation, and microbiota disorder. These factors exacerbate damage to the intestinal mucosal barrier. Spirulina platensis is a commercial alga with various biological activity that is widely used as a functional ingredient in food and beverage products. However, there have been few studies on the treatment of UC using S. platensis aqueous extracts (SP), and the underlying mechanism of action of SP against UC has not yet been elucidated. Herein, we aimed to investigate the modulatory effect of SP on microbiota disorders in UC mice and clarify the underlying mechanisms by which SP alleviates damage to the intestinal mucosal barrier. Dextran sulfate sodium (DSS) was used to establish a normal human colonic epithelial cell (NCM460) injury model and UC animal model. The mitochondrial membrane potential assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and staining with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) and Hoechst 33258 were carried out to determine the effects of SP on the NCM460 cell injury model. Moreover, hematoxylin and eosin (H&E) staining, transmission electron microscopy (TEM), enzyme-linked immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (qPCR), western blot, and 16S ribosomal DNA (rDNA) sequencing were used to explore the effects and underlying mechanisms of action of SP on UC in C57BL/6 mice. In vitro studies showed that SP alleviated DSS-induced NCM460 cell injury. SP also significantly reduced the excessive generation of intracellular reactive oxygen species (ROS) and prevented mitochondrial membrane potential reduction after DSS challenge. In vivo studies indicated that SP administration could alleviate the severity of DSS-induced colonic mucosal damage compared with the control group. Inhibition of inflammation and oxidative stress was associated with increases in the activity of antioxidant enzymes and the expression of tight junction proteins (TJs) post-SP treatment. SP improved gut microbiota disorder mainly by increasing antioxidant enzyme activity and the expression of TJs in the colon. Our findings demonstrate that the protective effect of SP against UC is based on its inhibition of pro-inflammatory cytokine overproduction, inhibition of DSS-induced ROS production, and enhanced expression of antioxidant enzymes and TJs in the colonic mucosal barrier.
